Positive impactIPO

Symbiotec Pharmalab IPO Lists at ₹988 After 75.06x Demand

Multibagg AI 1d ago·21 Nov 2026, 3:00 pm

The initial public offering of Symbiotec Pharmalab Ltd debuted on the exchange at an issue price of ₹988 per share. The offering was heavily subscribed, with demand roughly 75 times the number of shares on offer, signalling strong interest from retail and institutional investors. Symbiotec operates in the pharmaceutical manufacturing space, focusing on generic drug production and contract manufacturing services.

For investors, the high subscription level points to confidence in the company’s growth prospects and the broader pharma sector, but the listing price is set by the underwriters and may differ from the price the stock trades at once it hits the market. Market participants will be watching the opening trade for price volatility, the lock‑in period for promoters, and upcoming developments such as earnings releases, product pipeline updates, and regulatory approvals that could shape the stock’s performance.

Excerpt from Multibagg AI

Symbiotec listed at ₹988 per share on September 1, 2026, matching its final issue price. The ₹1,757 crore IPO was subscribed 75.06 times during August 24 to August 27, 2026. The offer included a ₹150 crore fresh issue and a ₹1,607 crore offer for sale. Symbiotec reported ₹872.26 crore revenue and ₹109.90 crore profit…
Read the original at Multibagg AI

Affected stocks

Bullish1 stock

Bull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.

Key takeaways

  • Concerns Symbiotec Pharmalab (SYMBIOTEC).
  • Category: IPO.
  • AI reads the tone as positive (potentially bullish) for the stock.
  • Assessed as a significant, market-relevant update.

Why it matters

A meaningful update for Symbiotec Pharmalab worth tracking. The tone is positive — historically associated with upward pressure, though not predictive. Use the price and stock snapshot to gauge how the market is responding.

Summary & analysis by DocStoX. Full story at Multibagg AI.

More IPO news

More news

Latest headlines

More news

Aggregated from third-party sources for research. Sentiment & impact are AI-generated, indicative, not advice.